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ABSTRACT 
Jennifer B. Harmon: Circulating Omentin-1 and Chronic Temporomandibular Disorder Pain 
(Under the direction of Anne E. Sanders) 
Objective: Literature implicates circulating inflammatory cytokines in pain and TMD.  One anti-
inflammatory adipokine, omentin-1, has decreased expression in inflammatory conditions.  This study 
tested the hypothesis that circulating levels of omentin-1 were lower in individuals with TMD than healthy 
controls.  Methods: A case-control design of chronic TMD cases (n=90) and TMD-free controls (n=54) 
were selected from the study named OPPERA.  Omentin-1 levels were measured in blood plasma 
samples using an enzyme-linked immunosorbent assay (ELISA).  Logistic regression estimated odds 
ratios (OR) and 95% confidence limits (CL) for the association between omentin-1 and TMD.  Results: 
Mean omentin-1 concentration was lower in TMD cases (413.5 µg/ml) than controls (464.8 µg/ml), but the 
difference was not statistically significant.  Odds of TMD decreased 36% per standard deviation increase 
in circulating omentin-1 (adjusted OR=0.64, 95% CL: 0.43, 0.96. P=0.031).  Conclusion: Decreased 
omentin-1 in TMD cases supports the view that TMD pain is mediated by anti-inflammatory pathways.
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INTRODUCTION 
 Idiopathic pain conditions account for a considerable portion of chronic pain disorders.  Prominent 
among these are temporomandibular disorders (TMD), chronic headaches, irritable bowel syndrome 
(IBS), interstitial cystitis/bladder pain syndrome (IC/BPS), low back pain, and widespread bodily pain such 
as fibromyalgia. 1 Because these conditions share etiological factors, individuals with pain commonly 
experience more than one chronic pain disorder. 
 TMD is the most common chronic orofacial pain condition. 2,3 According to the 2002 National 
Health Interview Survey, five percent of adults reported TMD-like pain. 4 The condition is characterized by 
pain in one or both temporomandibular joints and masticatory muscles, and limitations in jaw function.  
The pathogenesis of TMD is multifactorial, and risk factors commonly associated with chronic TMD pain 
include joint and muscle trauma, anatomical and pathophysiological factors, psychosocial factors and 
genetic factors. 1,5-7 
 Much of what is known about risk factors for TMD comes from cross-sectional studies.  Unlike 
those studies, the OPPERA study (Orofacial Pain: Prospective Evaluation and Risk Assessment) used a 
prospective cohort design.  It measured potential risk factors at baseline and followed TMD-free people 
over time finding that a greater number of comorbid pain conditions, psychological characteristics, clinical 
orofacial characteristics, sociodemographics characteristics, pain sensitivity, and cardiac autonomic 
function were factors that predicted first onset TMD incidence. 8 Another promising line of evidence 
suggests that inflammatory cytokines may contribute to the pathophysiology of TMD, 9 however 
inflammatory pathways have not yet been explored in OPPERA. 
 Pain disorders frequently coexists with inflammation and altered cytokine levels.  Cytokines are 
intracellular regulatory proteins secreted by specific cells of the immune system. 10 These proteins, 
especially proinflammatory cytokines, have been found in both chronic and acute pain conditions. 11 
Findings suggest that an increased level of cytokines contribute to the sensation of pain by increasing the 
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sensitization of nociceptors.  Cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha 
(TNF-α) are released during an inflammatory episode. 
 Heightened expression of proinflammatory mediators is characteristic of many pain conditions, 
implicating a role of inflammation in the pathophysiology of chronic pain.  Emerging research suggests 
that dysregulation of both pro- and anti-inflammatory mechanisms play a role in the induction and 
maintenance of pain. 12 
 Adipokines are a specific type of cytokine that are secreted predominantly by visceral adipose 
tissue.  Several studies have revealed an enhanced expression of pro-inflammatory adipokines in relation 
to obesity, type 2 diabetes, and cardiovascular disease. 13 Recently, omentin-1, an adipokine that is highly 
expressed in visceral adipose tissue, has attracted scientific interest because of its anti-inflammatory 
properties. 
 Omentin, also known as intelectin, is secreted mainly by cells of visceral adipose tissue 14 and 
exists in two forms, omentin-1 and omentin-2.  Omentin-1, the major circulating form, 15 was first 
associated with the pathophysiology of obesity-associated disorders and is down regulated in obesity.  
Therefore, downregulation of omentin-1 may undermine its protective capacity to play an anti-
inflammatory action. 
 Several studies provide evidence of downregulation of omentin-1 in chronic conditions with an 
inflammatory basis.  Shibata et al. for example, observed low levels of ometin-1 in patients with coronary 
artery disease. 16 Reduced levels of omentin have also been found in people with impaired glucose 
tolerance 17, suggesting that omentin-1 levels are negatively associated with cardiovascular diseases as 
well as with obesity-related disorders.  Plasma omentin-1 levels are significantly lower in people with 
obesity-linked metabolic dysfunction such as type 2 diabetes and coronary heart disease. 16,18 
Furthermore, reduced levels of omentin-1 are found in the synovial fluid of patients with rheumatoid 
arthritis. 19 Downregulation of omentin-1 may therefore undermine its protective capacity and contribute to 
these conditions. 
 Since decreased omentin-1 is related to obesity, it is intuitive to expect that obesity might be 
associated with chronic pain.  Cross-sectional studies have linked obesity to chronic headaches, 
abdominal pain, and arthritis.  These conditions may also occur in a state of chronic low-grade 
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inflammation, similar to TMD.  Obesity is an expression of systemic inflammation, making plausible an 
association between obesity and TMD.  In fact, in OPPERA, individuals with a higher body mass index 
(BMI) at baseline were at higher risk of developing first-onset TMD than those with lower BMI. 20 If 
omentin-1 plays a role in inflammation, and if inflammation is associated with the mechanism of obesity 
and TMD, then adipokines may play a role in the pathophysiology of TMD. 
 Since little is known about how anti-inflammatory proteins, specifically omentin-1, are associated 
with TMD this study sought to examine the role of one such anti-inflammatory cytokine.  The aim of this 
study was to compare levels of circulating omentin-1 in adults with and without chronic 
temporomandibular disorder.  We hypothesized that levels of plasma omentin-1 would be significantly 
lower in TMD cases than in TMD-free controls. 
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REVIEW OF THE LITERATURE 
Pain and Inflammation   
 Idiopathic pain conditions, meaning that the underlying cause of pain is unknown, account for a 
considerable portion of chronic pain disorders in the United States.  Prominent among these are 
temporomandibular disorders (TMD), chronic headaches, irritable bowel syndrome (IBS), interstitial 
cystitis/bladder pain syndrome (IC/BPS), low back pain, and widespread bodily pain such as 
fibromyalgia.1 Because these conditions share etiological factors, individuals with pain commonly 
experience more than one chronic pain disorder. 
Temporomandibular Disorder  
 TMD is the most common chronic orofacial pain condition. 2,3 According to the 2002 National 
Health Interview Survey, five percent of adults reported TMD-like pain. 4 The condition is characterized by 
pain in one or both temporomandibular joints and masticatory muscles, and limitations in jaw function.  
The pathogenesis of TMD is multifactorial, and risk factors commonly associated with chronic TMD pain 
include joint and muscle trauma, anatomical and pathophysiological factors, psychosocial factors and 
genetic factors. 1,5-7 
 Much of what is known about risk factors for TMD comes from cross-sectional studies.  Unlike 
those studies, the OPPERA study (Orofacial Pain: Prospective Evaluation and Risk Assessment) used a 
prospective cohort design.  It measured potential risk factors at baseline and followed TMD-free people 
over time finding that a greater number of comorbid pain conditions, psychological characteristics, clinical 
orofacial characteristics, sociodemographics characteristics, pain sensitivity, and cardiac autonomic 
function were factors that predicted first onset TMD incidence. 8 Another promising line of evidence 
suggests that inflammatory cytokines may contribute to the pathophysiology of TMD, 9 however 
inflammatory pathways have not yet been explored in OPPERA. 
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Cytokines 
 Pain disorders frequently coexists with inflammation and altered cytokine levels.  Cytokines are 
small intracellular regulatory proteins secreted by specific cells of the immune system. 10 Proinflammatory 
cytokines such as interleukin-8 (IL-8) promote inflammation, whereas anti-inflammatory cytokines 
suppress the activity of its counterpart.  These proteins, especially proinflammatory cytokines, have been 
found in both chronic and acute pain conditions. 11 Findings suggest that an increased level of cytokines 
contribute to the sensation of pain by increasing the sensitization of nociceptors.  Cytokines such as 
interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha (TNF-α) are released during an inflammatory 
episode. 
 Heightened expression of proinflammatory mediators is characteristic of many pain conditions, 
implicating a role of inflammation in the pathophysiology of chronic pain.  While proinflammatory 
cytokines play a role in pain induction, more research is needed to clarify the relationship between 
cytokines and chronic pain, especially TMD.  Emerging research suggests that dysregulation of both pro- 
and anti-inflammatory mechanisms play a role in the induction and maintenance of pain. 12  
Adipokines 
 Adipose tissue provides nutrient storage for triacyclycerols and houses differentiated cells called 
adipocytes, its most abundant cell population.  Adipokines are a specific type of cytokine that are 
secreted predominantly by visceral adipose tissue.  These proteins function as signaling molecules in 
many physiological and metabolic processes.  Inflammatory processes can be mediated by pro- and anti-
inflammatory adipokines.  Several studies have revealed an enhanced expression of pro-inflammatory 
adipokines in relation to obesity, type 2 diabetes, and cardiovascular disease. 13 Recently, omentin-1, an 
adipokine that is highly expressed in visceral adipose tissue, has attracted scientific interest because of 
its anti-inflammatory properties. 
Omentin-1: an anti-inflammatory adipokine 
 Omentin, also known as intelectin, is a novel adipokine secreted mainly by cells of visceral 
adipose tissue 14 and exists in two forms, omentin-1 and omentin-2.  Omentin-1, the major circulating form 
in human blood, 15 was first associated with the pathophysiology of obesity-associated disorders and is 
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down regulated in obesity.  Therefore, downregulation of omentin-1 may undermine its protective capacity 
to play an anti-inflammatory action. 
 Several studies provide evidence of downregulation of omentin-1 in chronic conditions with an 
inflammatory basis.  Shibata et al. for example, observed low levels of ometin-1 in patients with coronary 
artery disease. 16 Reduced levels of omentin have also been found in people with impaired glucose 
tolerance, 17 suggesting that omentin-1 levels are negatively associated with cardiovascular diseases as 
well as with obesity-related disorders.  Plasma omentin-1 levels are significantly lower in people with 
obesity-linked metabolic dysfunction such as type 2 diabetes and coronary heart disease. 16,18 
Furthermore, reduced levels of omentin-1 are found in the synovial fluid of patients with rheumatoid 
arthritis. 19 Downregulation of omentin-1 may therefore undermine its protective capacity and contribute to 
these conditions. 
 Since decreased omentin-1 is related to obesity, it is intuitive to expect that obesity might be 
associated with chronic pain.  Cross-sectional studies have linked obesity to chronic headaches, 
abdominal pain, and arthritis.  These conditions may also occur in a state of chronic low-grade 
inflammation, similar to TMD.  Obesity is an expression of systemic inflammation, making plausible an 
association between obesity and TMD.  In fact, in OPPERA, individuals with a higher body mass index 
(BMI) at baseline were at higher risk of developing first-onset TMD than those with lower BMI. 20 If 
omentin-1 plays a role in inflammation, and if inflammation is associated with the mechanism of obesity 
and TMD, then adipokines may play a role in the pathophysiology of TMD. 
Purpose 
 Since little is known about how anti-inflammatory proteins, specifically omentin-1, are associated 
with TMD this study sought to examine the role of one such anti-inflammatory cytokine.  The aim of this 
study was to compare levels of circulating omentin-1 in adults with and without chronic 
temporomandibular disorder.  We conducted experiments using cross-sectional data from patients with 
TMD and those with TMD and other comorbidities to test the following hypothesis: that levels of plasma 
omentin-1 would be significantly lower in TMD cases than in TMD-free controls. 
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INTRODUCTION AND REVIEW OF THE LITERATURE 
 Idiopathic pain conditions account for a considerable portion of chronic pain disorders.  Prominent 
among these are temporomandibular disorders (TMD), chronic headaches, irritable bowel syndrome 
(IBS), interstitial cystitis/bladder pain syndrome (IC/BPS), low back pain, and widespread bodily pain such 
as fibromyalgia. 1 Because these conditions share etiological factors, individuals with pain commonly 
experience more than one chronic pain disorder. 
 TMD is the most common chronic orofacial pain condition. 2,3 According to the 2002 National 
Health Interview Survey, five percent of adults reported TMD-like pain. 4 The condition is characterized by 
pain in one or both temporomandibular joints and masticatory muscles, and limitations in jaw function.  
The pathogenesis of TMD is multifactorial, and risk factors commonly associated with chronic TMD pain 
include joint and muscle trauma, anatomical and pathophysiological factors, psychosocial factors and 
genetic factors. 1,5-7 
 Much of what is known about risk factors for TMD comes from cross-sectional studies.  Unlike 
those studies, the OPPERA study (Orofacial Pain: Prospective Evaluation and Risk Assessment) used a 
prospective cohort design.  It measured potential risk factors at baseline and followed TMD-free people 
over time finding that a greater number of comorbid pain conditions, psychological characteristics, clinical 
orofacial characteristics, sociodemographics characteristics, pain sensitivity, and cardiac autonomic 
function were factors that predicted first onset TMD incidence. 8 Another promising line of evidence 
suggests that inflammatory cytokines may contribute to the pathophysiology of TMD, 9 however 
inflammatory pathways have not yet been explored in OPPERA. 
 Pain disorders frequently coexists with inflammation and altered cytokine levels.  Cytokines are 
intracellular regulatory proteins secreted by specific cells of the immune system. 10 These proteins, 
especially proinflammatory cytokines, have been found in both chronic and acute pain conditions. 11 
Findings suggest that an increased level of cytokines contribute to the sensation of pain by increasing the
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sensitization of nociceptors.  Cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor alpha 
(TNF-α) are released during an inflammatory episode. 
 Heightened expression of proinflammatory mediators is characteristic of many pain conditions, 
implicating a role of inflammation in the pathophysiology of chronic pain.  Emerging research suggests 
that dysregulation of both pro- and anti-inflammatory mechanisms play a role in the induction and 
maintenance of pain. 12 
 Adipokines are a specific type of cytokine that are secreted predominantly by visceral adipose 
tissue.  Several studies have revealed an enhanced expression of pro-inflammatory adipokines in relation 
to obesity, type 2 diabetes, and cardiovascular disease. 13 Recently, omentin-1, an adipokine that is highly 
expressed in visceral adipose tissue, has attracted scientific interest because of its anti-inflammatory 
properties. 
 Omentin, also known as intelectin, is secreted mainly by cells of visceral adipose tissue 14 and 
exists in two forms, omentin-1 and omentin-2.  Omentin-1, the major circulating form, 15 was first 
associated with the pathophysiology of obesity-associated disorders and is down regulated in obesity.  
Therefore, downregulation of omentin-1 may undermine its protective capacity to play an anti-
inflammatory action. 
 Several studies provide evidence of downregulation of omentin-1 in chronic conditions with an 
inflammatory basis.  Shibata et al. for example, observed low levels of ometin-1 in patients with coronary 
artery disease. 16 Reduced levels of omentin have also been found in people with impaired glucose 
tolerance, 17 suggesting that omentin-1 levels are negatively associated with cardiovascular diseases as 
well as with obesity-related disorders.  Plasma omentin-1 levels are significantly lower in people with 
obesity-linked metabolic dysfunction such as type 2 diabetes and coronary heart disease. 16,18 
Furthermore, reduced levels of omentin-1 are found in the synovial fluid of patients with rheumatoid 
arthritis. 19 Downregulation of omentin-1 may therefore undermine its protective capacity and contribute to 
these conditions. 
 Since decreased omentin-1 is related to obesity, it is intuitive to expect that obesity might be 
associated with chronic pain.  Cross-sectional studies have linked obesity to chronic headaches, 
abdominal pain, and arthritis.  These conditions may also occur in a state of chronic low-grade 
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inflammation, similar to TMD.  Obesity is an expression of systemic inflammation, making plausible an 
association between obesity and TMD. In fact, in OPPERA, individuals with a higher body mass index 
(BMI) at baseline were at higher risk of developing first-onset TMD than those with lower BMI. 20 If 
omentin-1 plays a role in inflammation, and if inflammation is associated with the mechanism of obesity 
and TMD, then adipokines may play a role in the pathophysiology of TMD. 
 Since little is known about how anti-inflammatory proteins, specifically omentin-1, are associated 
with TMD this study sought to examine the role of one such anti-inflammatory cytokine.  The aim of this 
study was to compare levels of circulating omentin-1 in adults with and without chronic 
temporomandibular disorder.  We hypothesized that levels of plasma omentin-1 would be significantly 
lower in TMD cases than in TMD-free controls. 
	   10 
MATERIALS AND METHODS 
Parent Study: OPPERA 
 The parent study, OPPERA, is an ongoing multisite prospective cohort study of risk factors for the 
development and persistence of TMD and other idiopathic pain disorders. 6 OPPERA’s objectives are to 
identify physiological, psychological, clinical, and genetic risk factors for the incidence of TMD. 21 At 
baseline OPPERA enrolled 3,263 participants with no lifetime experience of TMD.  Of these, 1,633 were 
selected at random for a baseline case-control study of chronic TMD. 22 Adults were recruited from 
communities in: Baltimore, Maryland; Buffalo, New York; Chapel Hill, North Carolina; and Gainesville, 
Florida.  Recruitment took place around these study sites between May 2006 and November 2008 using 
newspaper and radio station advertisements, university emails, flyers and word of mouth.  Eligible adults 
were aged 18 to 44 years in good health, with no history of facial trauma or surgery, no TMD symptoms 
or pain, no diagnosis of TMD, and an absence of TMD myalgia and arthralgia upon clinical examination.  
At baseline, all participants completed questionnaires evaluating behavioral, social, and psychological 
characteristics related to TMD.  An extensive comprehensive clinical examination measured responses to 
standardized noxious stimuli that measured pain amplification, cardiovascular function, and psychological 
characteristics.  Anthropometric measurements were also determined and a blood draw was performed. 
Omentin Ancillary Study 
 Subjects in this ancillary case-control study were drawn from a second case-control OPPERA 
study of chronic pain. Examiner-classified chronic TMD cases (n = 90) had experienced TMD symptoms 
for at least 6 months.  Controls (n = 55) were a random sample of enrollees in the prospective cohort 
study who were examiner-verified to not have TMD.  Exclusion criteria were the same as the OPPERA 
study-wide exclusion criteria: currently in orthodontic treatment, heart disease or heart failure, kidney 
failure or renal dialysis, uncontrolled diabetes, pregnant or nursing, uncontrolled respiratory disease, 
uncontrolled hypertension, hyperthyroidism, drug or alcohol abuse, epilepsy, chemotherapy or radiation 
therapy, and psychiatric disorders that have required hospitalization.
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TMD Classification 
 All OPPERA participants underwent a clinical examination based on the Research Diagnostic 
Criteria for TMD 23 performed by trained and calibrated examiners.  TMD case status was confirmed 
based on: 1) pain experienced for at least 5 days per month in masticatory structures; and 2) confirmation 
of TMD arthralgia (pain of either temporomandibular joint during jaw movement or digital palpation) and/or 
myalgia (pain during jaw movement in at least 3 of the 8 muscle groups based on evaluation of 
temporalis, masseter, lateral pterygoid, and submandibular muscles). 
Coexisting Pain Conditions 
 At baseline, other pain conditions such as headache, chronic back pain, and IBS were evaluated 
using the Comprehensive Pain and Symptom Questionnaire (CPSQ).  Participants were asked whether 
they had any headaches in the past year (yes/no).  Those answering affirmatively were then asked to 
differentiate their headaches into stress or tension type, migraine, hunger headache, or sinus headache. 
To measure headache severity and headache types, participants were asked questions for initial 
characterization.  Questions regarding pains other than the face, current back pain, and number of back 
pain episodes in the past 12 months were also asked.  Participants answered four questions about 
abdominal pain using the Rome III IBS classification for irritable bowel syndrome. 24  Information was also 
collected on IBS symptoms over the referent period of the last 3 months. 
Body Mass Index 
 Body mass index (BMI) was calculated as weight in kilograms divided by height in meters 
squared (kg/m2) and categorized using standard World Health Organization categories of: underweight 
and normal combined (<25.00); overweight (25.00–29.99); and obese (≥30.0). 
Blood Plasma Collection and Storage 
 A 20-mL sample of peripheral blood was obtained by venipuncture from OPPERA study 
participants at enrollment for further DNA investigation and genotyping. 22 Blood samples were 
centrifuged for at least 12 minutes and plasma was quickly frozen and stored at -80°C in 5-mL EDTA 
tubes containing polyethylene vacutainers. 
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Omentin-1 Assessment 
 Plasma omentin-1 levels were assessed using an enzyme linked immunosorbent assay 
(BioVendor Research and Diagnostic Products; Asheville, NC) according to kit instructions.  All plasma 
samples were diluted at 40x. 
Statistical Power and Sample Size 
 The sample size calculation was guided by estimates of serum omentin-1 levels for obstructive 
sleep apnea (OSA) cases and healthy controls reported by Wang et al. 25 where the median (IQR) serum 
omentin-1 level for cases was 11.29 ng/mL (0.02—15.13) and for controls was 22.62 ng/mL (18.71–
27.21); a two-fold effect.  To permit a less extreme effect size, we specified a two-sample means test 
setting the mean for controls as 22.0 ng/mL and allowing the means for cases to be 10.0, 12.0, 14.0 or 
16.  Assuming equal size groups, an alpha of 0.05, power of 0.8, a pooled standard deviation of 13.0 and, 
the minimum number of subjects required for the case and control groups combined was 40, 56, 86 and 
150 respectively.  We conservatively chose a sample size of 150 (n=75 subjects per group), allowing for a 
difference between cases and controls of 6 ng/ml. 
Statistical Analysis 
 Statistical analyses were conducted using STATA (StataCorp., College Station, TX, USA, 
Release 13.1).  The dependent variable was TMD case status and the exposure was plasma omentin-1 
levels.  Omentin-1 values were standardized as z-scores to aid in interpretation of statistical estimates. 
Box-and-whisker plots (median, min-max) reported omentin-1 levels in controls, subjects with only TMD 
and subjects with TMD plus another pain condition.  Binary logistic regression was used to calculate the 
odds ratio values (ORs) and 95% confidence intervals (CIs) for TMD.  Finally, multivariate analysis 
adjusted for potential confounding covariates of study site, age, sex, and BMI. 
IRB 
 Institutional review boards at all four study sites approved study procedures for OPPERA, and 
participants provided informed consent.  This study was approved by the Biomedical Institutional Review 
Board of the University of North Carolina at Chapel Hill (UNC). 
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RESULTS 
 One study participant was omitted from analysis due to an inadequate amount of blood plasma 
needed to measure omentin-1 levels.  The final sample comprised 106 females and 38 males (Table 1). 
In unadjusted analysis, mean omentin levels were lower in TMD cases than controls, but failed to reach 
statistical significance (P=0.072, Table 2).  There were no significant differences in sex, age, and BMI 
between cases and controls.  Following adjustment for study site, age, sex, and BMI (Table 3) odds of 
TMD were 36% lower per standard deviation increase in circulating omentin-1 (OR=0.64, 95% CL: 0.43, 
0.96, P=0.031).  Odds of TMD were 2.7-fold higher in women than men.  As compared to cases with ≥ 1 
comorbid pain conditions (n = 72) and pain free participants (n = 54), median plasma omentin-1 levels 
were lower in cases with TMD only (n = 18) (Fig. 1). 
	   14 
DISCUSSION 
 In this case-control study, ancillary to OPPERA, omentin-1 levels were lower in TMD cases than 
controls after adjustment for potential confounding.  The fact that omentin-1 was measured in plasma, 
indicates that heightened inflammation in TMD is not confined to the temporomandibular tissues. 
 In in vitro studies, omentin-1 inhibited TNFα-induced vascular inflammation in human endothelial 
cells. 26 In another study, omentin-1 played a similar anti-inflammatory role by preventing the TNFα-
induced inflammatory responses in vascular smooth muscle cells. 27 Kim and colleagues further showed 
that TNF-α, along with several interleukin cytokines, were detected in the synovial fluid of TMD cases as 
compared to healthy controls. 28 These studies suggest that omentin, in addition to its systemic effect, 
inhibits a specific inflammatory cytokine that is present in the joint of TMD cases. 
 Our finding of decreased omentin-1 levels in cases is similar to results from other studies.  A 
recent study revealed that omentin-1 levels were significantly lower in patients with inflammatory bowel 
disease. 29 In another study, decreased secretion of omentin-1 in the synovial fluid of painful knee 
osteoarthritis was much lower than omentin-1 levels in the serum of these patients (2.49 vs. 23.76 
µg/L).30 
 Lower omentin-1 concentration was found in blood plasma (taken via venipuncture) for those 
subjects with TMD only.  Potential confounding effects of other cytokines may provide the answer as to 
why omentin-1 levels of the TMD plus another pain group were more similar to the control group.  The 
findings from Slade and colleagues regarding levels of MCP-1 are similar to the findings in our study in 
that levels of the cytokines are TMD specific. 9 Even though our study did not find a statistically significant 
difference of omentin-1 levels between the control group and group with TMD plus another pain condition, 
omentin levels tended to be lower.  Similarly in Slade et al., MCP-1 cytokine levels were only significantly 
associated with TMD in the absence of widespread pain.
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 There is a growing interest in identifying potential diagnostic biomarkers for pain in patients with 
TMD.  For example, Slade and colleagues found that cytokine profiles differed among cases stratified on 
the basis of comorbid widespread palpation tenderness. 9 Elevated levels of various circulating 
inflammatory markers such as cytokine IL-8 were associated with TMD and widespread pain; whereas 
MCP-1 levels were associated with TMD only in the absence of widespread pain. 
 Recently, the relationship between proinflammatory cytokines and temporomandibular joint (TMJ) 
inflammation has been examined. 9,31 The release of TNF-α along with interleukins occurs in conjunction 
with TMJ inflammation. 31 These proinflammatory cytokines play a role in articular cartilage remodeling 
and deterioration as seen in osteoarthritis.  Changes in the cartilage become noticeable via swelling and 
redness due to the nociceptors of the TMJ being stimulated by these inflammatory mediators.  Moreover, 
Slade et al. 9 showed that in TMD cases and widespread pain, levels of the anti-inflammatory IL-1RA were 
lower. 
 Based on the emerging collective evidence for omentin-1 in epidemiologic studies, low levels of 
omentin exacerbate the putative effects of proinflammatory mediators.  Therefore it is conceivable that a 
decrease in omentin-1 levels may be involved in the pathophysiology of TMD.  Further studies are 
needed to clearly elucidate the plausible mechanism by which omentin-1 may contribute to persistent 
pain and development of pain.  This information could motivate development of effective interventions to 
increase omentin-1 levels and other anti-inflammatory cytokines in an attempt to decrease inflammation, 
thereby reducing existing pain or preventing the development of new pain. 
Strengths and Limitations 
 The ancillary case-control design, took advantage of the established infrastructure, protocols and 
rich dataset of the OPPERA parent study.  Multiple study sites and community recruitment optimized the 
diversity and representativeness of the study population to improve the generalizability of the findings. 
 Potential limitations of this study merit consideration.  First, the total number of participants in the 
ancillary case-control study was small.  In addition, factors with the potential to affect inflammation such 
as alcohol, smoking, and medications were not controlled for during statistical analyses. 
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CONCLUSIONS 
 Circulating levels of omentin-1 were lower in TMD cases than controls, suggesting a potential 
protective effect of omentin-1 against TMD pain mediated by anti-inflammatory pathways.  
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TABLES 
Table 1. Characteristics of chronic TMD cases and pain-free controls (column percentages), n=144 
 
  N Percent   
TMD Case  
(n=90) 
Control  
(n=54)  P-value 
Sex 
   
  
 Male 38 26.4
 
21.1 35.2 0.064 
Female 106 73.6 
 
78.9 64.8 
 
    
  
 Age (years) 
   
  
 18–24 55 38.2
 
32.2 48.2 0.452 
25–29 32 22.2 
 
24.4 18.5 
 30–34 20 13.9 
 
15.6 11.1 
 35–39 18 12.5 
 
13.3 11.1 
 40–44 19 13.2 
 
14.4 11.1 
 
    
  
 Body mass index (kg/m2) 
   
  
 Unweight/healthy (<25.00) 83 57.6
 
57.3 61.5 0.691 
Overweight (25.00–29.99) 34 23.6 
 
23.6 25.0 
 Obese (≥30.00) 24 16.7 
 
19.1 13.5 
 Missing 3 2.1 
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Table 2: Mean (std. dev.) circulating omentin-1 concentration (µg/ml) 
 
 
Mean Std. dev. P-value 
TMD case status 
   
Case 413.5 145.9 0.072 
Control 464.8 191.8 
 
    Sex 
   
Male 436.8 149.3 0.861 
Female 431.3 172.0 
 
    Age (years) 
   
18–24 408.4 141.4 0.174 
25–29 452.9 181.7 
 
30–34 496.4 224.5 
 
35–39 383.8 106.2 
 
40–44 448.7 167.7 
 
    Body mass index (kg/m2) 
       
Unweight/healthy (<25.00) 423.6 159.2 0.289 
Overweight (25.00–29.99) 469.7 194.8 
 
Obese (≥30.00) 407.8 137.6  
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Table 3. Multivariate-adjusted association between standardized omentin-1 concentration and TMD (odds 
ratio (OR) and 95% confidence limits (CL), n=141 
 
 
Site-adjusted  
OR (95% CL) 
P-
value  
Multivariate-adjusted  
OR (95% CL) P-value 
      Standardized omentin 
(z-score) 0.70 (0.48, 1.02) 0.066 
 
0.64 (0.43, 0.96) 0.031 
Sex 
     Male 
   
Ref  
 Female 
   
2.74 (1.13, 6.68) 0.026 
Age (years) 
     18-24 
   
Ref 
 25-29 
   
1.76 (0.63, 4.92) 0.280 
30-34 
   
2.94 (0.79, 10.95) 0.108 
35-39 
   
1.31 (0.37, 4.67) 0.681 
40-44 
   
2.17 (0.59, 7.93) 0.242 
Body mass index (kg/m2) 
     Unweight/healthy (<25.00) 
   
Ref 
 Overweight (25.00–29.99) 
   
1.29 (0.50, 3.33) 0.603 
Obese (≥30.00) 
   
1.51 (0.48, 4.73) 0.482 
Intercept 0.60 (0.26, 1.40) 0.239 
 
0.17 (0.04, 0.62) 0.008 
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Figure 1. Box and whisker plot depicting plasma omentin-1 concentration (µg/ml) in pain-free controls (No 
pain, n=54), TMD cases with no other pain conditions (TMD only, n=18) and TMD cases with ≥1 other 
pain condition (TMD plus, n=72). Other pain conditions are migraine, low back pain or irritable bowel 
syndrome. The median value is the horizontal line subdividing the box. The length of the box represents 
the interquartile range (IQR). Whiskers extend to 1.5 IQR of the nearest quartile. Solid circles represent 
outlying values.  Plasma omentin-1 levels are reduced only in TMD patients. 
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